UK Site Head & Scientific Director
Pharmaceutical
Oxford BioTherapeutics
Switzerland
Dr. Boyd brings more than 20 years' experience in therapeutic antibody target discovery to OBT. He joined OBT from the MRC Toxicology Unit where as a senior investigator he identified novel lymphoma targets. He was previously head of proteome biology at Oxford Glycosciences where he led its oncology target discovery team. Dr. Boyd holds a PhD in Biochemistry from Sussex University and conducted post-doctoral research at the Royal Postgraduate Medical School and the Imperial Cancer Research Fund.
Biochemistry